Worldwide, at least 46.8 million people are believed to be living with Alzheimer’s disease or other dementia. If breakthroughs are not discovered, this number could exceed 131.5 million by 2050. How can public and private collaboration reinvigorate the R&D pipeline for this tragic illness?
The System Initiative for this session is Shaping the Future of Health and Healthcare.
– Andrea Pfeifer, Chief Executive Officer, AC Immune, Switzerland
– Paul Stoffels, Vice-Chairman and Chief Scientific Officer, Johnson & Johnson, USA
– Michel Vounatsos, Chief Executive Officer, Biogen, USA
– P. Murali Doraiswamy, Professor of Psychiatry and Medicine, Duke University Medical Center, USA